Difference between revisions of "Thyroid cancer, BRAF-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "www.ncbi.nlm.nih.gov/pubmed" to "pubmed.ncbi.nlm.nih.gov") Tags: mobile edit mobile web edit |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable sortable" style="width: 75%; text-align:center;"" to "{| class="wikitable sortable" style="width: 60%; text-align:center;"") |
||
Line 15: | Line 15: | ||
===Regimen {{#subobject:7fb6ac|Variant=1}}=== | ===Regimen {{#subobject:7fb6ac|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
!style="width: 33%"|Years of enrollment | !style="width: 33%"|Years of enrollment |
Revision as of 01:17, 1 July 2021
Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.
2 regimens on this page
2 variants on this page
|
Differentiated thyroid cancer, all lines of therapy
Vemurafenib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Brose et al. 2016 (NO25530) | 2011-2013 | Phase II |
Note: this study was in patients with papillary thyroid cancer, only.
Targeted therapy
- Vemurafenib (Zelboraf) 960 mg PO twice per day
Continued indefinitely
References
- NO25530: Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1272-82. Epub 2016 Jul 23. link to original article contains verified protocol link to PMC article PubMed NCT01286753
Anaplastic thyroid cancer, all lines of therapy
Dabrafenib & Trametinib
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence | Efficacy |
---|---|---|---|
Subbiah et al. 2017 (BRF117019) | 2014-2016 | Phase II, <20 pts in subgroup (RT) | ORR: 63% (95% CI, 35-85) |
Patients in this subgroup had previously treated anaplastic thyroid cancer with BRAF p.V600E mutation.
Targeted therapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
Continued indefinitely
References
- BRF117019: Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018 Jan 1;36(1):7-13. Epub 2017 Oct 26. link to original article contains verified protocol link to PMC article PubMed NCT02034110